iShares U.S. Healthcare ETF News - June 2026
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding Research Tools
Merck KGaA will acquire U.S. biotech firm Bio-Techne for $11.3 billion. The all-cash offer provides $73 per share to Bio-Techne investors. This price...
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding High-Growth Life Sciences
Merck KGaA entered a definitive agreement to acquire Bio-Techne Corp. for $73 per share in cash. The transaction represents a total enterprise value of...
Pfizer settles 5,000 lawsuits, resolving Depo-Provera brain tumor claims
Pfizer reached a settlement in principle to resolve more than 5,000 lawsuits involving its Depo-Provera birth control shot. A Monday court filing confirmed the...
GSK acquires Nuvalent for $10.6B, targeting blockbuster lung cancer drugs
GSK signed a definitive agreement to acquire Nuvalent for $10.6 billion. The transaction secures a portfolio of next-generation precision cancer therapies and...
Eli Lilly surges, fueled by 30% weight loss for retatrutide
Eli Lilly released late-stage clinical trial data for its next-generation weight-loss drug, retatrutide. The drug led to a 30.3% average reduction in body...
Novo Nordisk Oral Wegovy Hits 3M Prescriptions, Expanding Obesity Treatment Market
Novo Nordisk’s oral Wegovy surpassed three million U.S. prescriptions since its January 2026 launch. This volume represents one of the most successful...
Johnson & Johnson’s Erleada cuts prostate cancer metastasis risk by 20%
Johnson & Johnson reported that ERLEADA (apalutamide) combined with hormone therapy reduced the risk of metastasis or death by 20% in high-risk prostate cancer...